...
首页> 外文期刊>Bioorganic and Medicinal Chemistry Letters >Lead optimization of apyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies
【24h】

Lead optimization of apyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies

机译:领先优化apyrazolo [1,5-a] pyrimidin-7(4H)-one支架,以鉴定适用于体内生物学研究的有效,选择性和口服生物利用度的KDM5抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Starting with a lead [1,5-a]pyrimidin-7(4H)-one-containing molecule (1), we generated potent, selective and orally bioavailable KDM5 inhibitors. Using structure- and property-based approaches, we designed 48 with improved cell potency (PC9 H3K4Me3 EC50 = 0.34 mu M). Furthermore, 48 maintained suitable physiochemical properties and displayed an excellent pharmacokinetic (PK) profile in mice. When dosed orally in mice at 50 mg/kg twice a day (BID), 48 showed an unbound maximal plasma concentration (C-max) >15-fold over its cell EC50, thereby providing a robust chemical probe for studying KDM5 biological functions in vivo. (C) 2016 Elsevier Ltd. All rights reserved.
机译:从含[1,5-a]嘧啶-7(4H)-一的先导分子(1)开始,我们生成了有效的,选择性的和口服可生物利用的KDM5抑制剂。使用基于结构和属性的方法,我们设计了48个具有改进的细胞效能(PC9 H3K4Me3 EC50 = 0.34μM)。此外,48维持适当的理化特性,并在小鼠中显示出出色的药代动力学(PK)档案。当每天以50 mg / kg的剂量每天两次在小鼠中口服给药(BID)时,48的最大血浆浓度(C-max)超过其细胞EC50的15倍,从而为研究KDM5的生物学功能提供了可靠的化学探针体内。 (C)2016 Elsevier Ltd.保留所有权利。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号